Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Assets (2020 - 2025)

Insight Molecular Diagnostics' Assets history spans 6 years, with the latest figure at $43.9 million for Q3 2025.

  • For Q3 2025, Assets fell 37.43% year-over-year to $43.9 million; the TTM value through Sep 2025 reached $43.9 million, down 37.43%, while the annual FY2024 figure was $35.1 million, 53.16% down from the prior year.
  • Assets for Q3 2025 was $43.9 million at Insight Molecular Diagnostics, down from $50.5 million in the prior quarter.
  • Across five years, Assets topped out at $177.4 million in Q2 2021 and bottomed at $35.1 million in Q4 2024.
  • The 5-year median for Assets is $82.8 million (2023), against an average of $102.2 million.
  • The largest annual shift saw Assets skyrocketed 191.37% in 2021 before it tumbled 53.16% in 2024.
  • A 5-year view of Assets shows it stood at $159.6 million in 2021, then plummeted by 37.27% to $100.1 million in 2022, then fell by 25.18% to $74.9 million in 2023, then crashed by 53.16% to $35.1 million in 2024, then grew by 25.24% to $43.9 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Assets are $43.9 million (Q3 2025), $50.5 million (Q2 2025), and $60.4 million (Q1 2025).